Amoxapine: a review of its pharmacology and efficacy in depressed states.
Amoxapine is an N-demethylated dibenzoxazepine closely related in the neuroleptic loxapine. Its tricyclic structure appears to give it antidepressant properties resembling imipramine and amitriptyline. In uncontrolled trials it was shown to have antidepressant activity in usual doses up to 200 to 400mg daily. In placebo and double-blind controlled studies comparing amoxapine with the standard tricyclic antidepressants imipramine and amitriptyline, it was shown to be comparable in efficacy with a possibly somewhat faster onset of improvement of selected symptoms of depression in some studies. Because of the small study groups and lack of placebo control, many reports do not show statistically significant differences of treatment over standard drugs. To date there have been no studies comparing amoxapine with electroconvulsive therapy. Side effects were qualitatively similar to standard drugs with a suggestion that in standard doses or overdose myocardial effects are mild. However, the final place of amoxapine in the therapy of depressed states is still to be decided.
D000657:Amoxapine / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000506:poisoning / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D003989:Dibenzoxazepines / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics
D000929:Antidepressive Agents, Tricyclic; D003989:Dibenzoxazepines; D000657:Amoxapine